Midi Health, a virtual care clinic for women 35 and older, has announced the launch of a Survivorship Program. This program aims to provide menopause care for breast cancer survivors and women at high risk for breast cancer.
The program was developed and is led by Dr. Mindy Goldman, a Clinical Professor in the Department of OB/GYN at UC San Francisco and founder of UCSF’s Gynecology Center for Cancer Survivors and At-Risk Women. Dr. Goldman also serves as Chief Clinical Officer for Midi Health.
Dr. Goldman stated: “Because of mistaken and outdated thinking around hormone therapy and risk factors for breast cancer, far too many women needlessly suffer through symptoms of midlife hormonal change without getting the relief and care they deserve.”
The Survivorship Program offers a range of treatment options, advice, and counseling based on recent research. Patients receive personalized treatment plans overseen by specialized clinicians who work with their existing medical teams.
Midi Health reports that misunderstandings about hormone therapy (HT) and breast cancer risk stem from initial findings of the 2002 Women’s Health Initiative study, which have since been largely reconsidered. More recent data suggests that estrogen may actually decrease the risk of breast cancer, and newer formulations of progesterone may not raise the risk at all.
Despite this, current data shows that less than 2% of women over 40 are taking hormone therapy for menopausal symptoms, a significant drop from the 40% who used HT before the 2002 study.
Joanna Strober, CEO and Co-Founder of Midi Health, said: “We are excited to be the first company of our kind to dive deep into this kind of personalized care, investing in research and development of evidence-based protocols specifically designed to address this higher-risk population of women and ensure they get the care they need and deserve.”
